Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 102 от 154

Активно (без набиране) Фаза 3

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

Polymyalgia Rheumatica

The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.

Начало: 28.06.2024 Край: 22.08.2028 Възраст: 50–100 г. Лечение

Argentina, Australia, Belgium +18 Novartis Pharmaceuticals NCT06331312

Активно (без набиране) Фаза 1

A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults

Healthy Volunteers With Hyperlipidemia

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on healthy participants with an elevated level of blood lipids (eg, cholesterol and triglycerides). The aim of the study is to see how safe and tolerable the study drug is in healthy adult participants. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Начало: 27.06.2024 Край: 04.12.2026 Възраст: 18–65 г. Лечение

New Zealand Regeneron Pharmaceuticals NCT06452771

Активно (без набиране) Фаза 3

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

Gout Arthritis, Gouty Hyperuricemia Gout Chronic

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months

Начало: 26.06.2024 Край: 01.11.2026 Възраст: 18–85 г. Лечение

Australia, Hong Kong, New Zealand +2 Arthrosi Therapeutics NCT06439602

Активно (без набиране) Фаза 2

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Alpha 1-Antitrypsin Deficiency Emphysema

Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema

Начало: 20.06.2024 Край: 30.09.2028 Възраст: 18–80 г. Лечение

Australia, Denmark, Ireland +6 Sanofi NCT05897424

Активно (без набиране) Фаза 3

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Large B-cell Lymphoma

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).

Начало: 19.06.2024 Край: 20.11.2029 Възраст: 18–80 г. Лечение

Argentina, Australia, Brazil +32 Celgene NCT06356129

Активно (без набиране)

Performance and Hearing-related Outcomes in Adults Implanted With the CI622D Dexamethasone-eluting Cochlear Implant Compared to Those Implanted With a Standard Cochlear Implant (CI622)

Hearing Loss, Bilateral Sensorineural Hearing Loss, Sensorineural Hearing Loss, Bilateral Hearing Loss, Cochlear

This clinical study will test a newly developed cochlear implant known as CI622D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation, which is common after any surgical procedure. The goal is to learn if there are added benefits in implant performance and hearing outcomes with the dexamethasone-releasing cochlear implant (CI622D) vs. the standard cochlear implant (CI622) without dexamethasone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing ability and their overall general health.

Начало: 17.06.2024 Край: 01.05.2026 Възраст: от 18 г. Лечение

Australia, France, Germany +1 Cochlear NCT06424262

Активно (без набиране) Фаза 3

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

Hypochondroplasia

The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).

Начало: 17.06.2024 Край: 01.08.2026 Възраст: 3–17 г. Лечение

Australia, Canada, France +6 BioMarin Pharmaceutical NCT06455059

Активно (без набиране) Фаза 3

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Alzheimer's Disease Dementia Alzheimer's Disease, Familial

This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.

Начало: 10.06.2024 Край: 01.06.2030 Възраст: от 18 г. Лечение

Australia, United Kingdom, United States Washington University School of Medicine NCT06384573

Активно (без набиране) Фаза 1

Pilot Study of the Coronary Spur Stent for In-stent Restenosis (DEEPER CORONARY)

In-stent Restenosis

To demonstrate acceptable short term safety rates of the Drug-eluting Coronary Spur Stent System as a primary treatment for coronary in-stent restenosis.

Начало: 09.06.2024 Край: 01.07.2026 Лечение

New Zealand ReFlow Medical, Inc. NCT06117150

Активно (без набиране) Фаза 1

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).

Начало: 07.06.2024 Край: 03.03.2027 Възраст: от 18 г. Лечение

Australia, Canada, France +8 Janssen Research & Development, LLC NCT06425991

Активно (без набиране) Фаза 2/3

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.

Начало: 07.06.2024 Край: 01.03.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Exelixis NCT06082167

Активно (без набиране) Фаза 2

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

Alopecia Areata

This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and safety of subcutaneous (SC) injections of amlitelimab treatment as monotherapy in participants aged 18 years and older with severe alopecia areata (AA). At the end of the double-blind treatment period, all participants will have the option to enter the open-label extension (OLE) period. The study duration will be up to 160 weeks for participants entering the OLE period including a 2-to-4-week screening, a 36-week randomized double-blind period, an optional OLE period (104 weeks) and a 16-week safety follow-up. The open-label extension period is optional and open to all participants who have completed the double-blind treatment period. The total number of visits will be up to 38 visits (or 12 visits for those not entering the OLE study).

Начало: 06.06.2024 Край: 05.01.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Bulgaria +13 Sanofi NCT06444451

Активно (без набиране) Фаза 3

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Extensive-Stage Small-Cell Lung Cancer Small-Cell Lung Cancer

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

Начало: 05.06.2024 Край: 30.09.2028 Възраст: 18–99 г. Лечение

Argentina, Australia, Belgium +23 Amgen NCT06211036

Активно (без набиране)

Responding to Late Effects in Survivors of Childhood Cancer

Survivorship Model of Care Support

Survivors of childhood cancer need ongoing support to navigate their needs after cancer treatment. Using technology may offer us new ways to collect and share information about cancer survivorship follow-up with young survivors, their carers, and primary care providers. Through the support of the Kids Cancer Project, in Phase 1 of this study, will co-design an electronic survivorship 'portal' that links young survivors with their cancer treatment information, and health care teams. In later Phases we will implement and evaluate the survivorship portal.

Начало: 01.06.2024 Край: 01.12.2026 Възраст: до 35 г. Поддържаща грижа

Australia Remziye Semerci NCT06586502

Активно (без набиране) Фаза 3

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Age Related Macular Degeneration (ARMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.

Начало: 30.05.2024 Край: 01.09.2027 Възраст: от 55 г. Лечение

Czechia, Germany, Hungary +5 Stealth BioTherapeutics Inc. NCT06373731

Активно (без набиране)

A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM

Headache Migraine Chronic

Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.

Начало: 29.05.2024 Край: 01.05.2031 Възраст: от 22 г. Превенция

Australia, United States ShiraTronics NCT06167655

Активно (без набиране)

First-in-human Trial of Home Brain Pressure Measured Using Kitea ICP Sensor, Placed During Hydrocephalus Shunt Surgery.

Hydrocephalus

Patients with hydrocephalus have an abnormal build-up of fluid around the brain and need a tube surgically implanted to drain that fluid. Patients and their caregivers live with the constant fear that the tube will block. Warning symptoms include irritability, headaches and vomiting. Unfortunately, there is no way of telling when fluid build-up is causing a rise in brain pressure and potentially impeding blood flow to the brain (life threatening) except for a brain scan in hospital and possibly hospitalisation. The investigators want to improve the lives of patients with hydrocephalus. They have developed a tool for parents and caregivers to monitor the pressure in the brain remotely via a sensor placed alongside the drainage tube. The device has been shown to be safe and to give reliable brain pressure readings using a large animal model (sheep). This study is a first-in-human safety study to show it is safe for patient use.

Начало: 27.05.2024 Край: 01.04.2026 Възраст: от 1 г. Лечение

New Zealand University of Auckland, New Zealand NCT06402786

Активно (без набиране) Фаза 2

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Asthma

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Начало: 24.05.2024 Край: 11.12.2026 Възраст: 18–75 г. Лечение

Argentina, Australia, Bulgaria +16 Amgen NCT06376045

Активно (без набиране) Фаза 3

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Hypertriglyceridemia

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.

Начало: 21.05.2024 Край: 01.09.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Bulgaria +12 Arrowhead Pharmaceuticals NCT06347133

Активно (без набиране)

The OPBC-07/microNAC Study

Breast Cancer

The aim of this multicenter retrospective cohort study is to determine the safety of omission of axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy.

Начало: 15.05.2024 Край: 01.06.2025 Възраст: 18–100 г.

Argentina, Australia, Brazil +23 University Hospital, Basel, Switzerland NCT06529302

1 … 100 101 102 103 104 … 154